258 related articles for article (PubMed ID: 33962475)
1. Advanced Adrenocortical Carcinoma: Current Perspectives on Medical Treatment.
Araújo AN; Bugalho MJ
Horm Metab Res; 2021 May; 53(5):285-292. PubMed ID: 33962475
[TBL] [Abstract][Full Text] [Related]
2. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature.
Brabo EP; Moraes AB; Neto LV
J Endocrinol Invest; 2020 Nov; 43(11):1531-1542. PubMed ID: 32468513
[TBL] [Abstract][Full Text] [Related]
3. Conventional chemotherapy and emerging targeted therapy for advanced adrenocortical carcinoma.
Xu YZ; Zhu Y
Anticancer Agents Med Chem; 2013 Feb; 13(2):248-53. PubMed ID: 22934700
[TBL] [Abstract][Full Text] [Related]
4. Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
Casey RT; Giger O; Seetho I; Marker A; Pitfield D; Boyle LH; Gurnell M; Shaw A; Tischkowitz M; Maher ER; Chatterjee VK; Janowitz T; Mells G; Corrie P; Challis BG
Semin Oncol; 2018 Jun; 45(3):151-155. PubMed ID: 30262398
[TBL] [Abstract][Full Text] [Related]
5. New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
[TBL] [Abstract][Full Text] [Related]
6. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic treatment of adrenocortical carcinoma.
Ahlman H; Khorram-Manesh A; Jansson S; Wängberg B; Nilsson O; Jacobsson CE; Lindstedt S
World J Surg; 2001 Jul; 25(7):927-33. PubMed ID: 11572034
[TBL] [Abstract][Full Text] [Related]
9. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
10. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
11. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
12. Next-generation therapies for adrenocortical carcinoma.
Altieri B; Ronchi CL; Kroiss M; Fassnacht M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101434. PubMed ID: 32622829
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
14. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical carcinoma: current treatment options.
De Filpo G; Mannelli M; Canu L
Curr Opin Oncol; 2021 Jan; 33(1):16-22. PubMed ID: 33186181
[TBL] [Abstract][Full Text] [Related]
16. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
17. Current Status and Future Targeted Therapy in Adrenocortical Cancer.
Alyateem G; Nilubol N
Front Endocrinol (Lausanne); 2021; 12():613248. PubMed ID: 33732213
[TBL] [Abstract][Full Text] [Related]
18. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
19. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
20. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
